For the study, which has not been peer-reviewed, researchers from Imperial College London examined the outcomes of 803 COVID-19 patients who required intensive care. About half of the patients received either the arthritis drug tocilizumab or sarilumab, while the other half received standard care.
The death rate for patients who received tocilizumab or sarilumab was 27 percent, compared to 36 percent for patients in the control group. Patients who took the arthritis drugs were able discontinue use of certain machines and medications needed to support lung or heart health sooner and were discharged a few days earlier than patients who did not receive the medications, according to The New York Times.
The study’s findings contradict numerous clinical trials, which found arthritis drugs did not benefit COVID-19 patients, including those from Sanofi and Novartis.The new findings spurred Britain on Jan. 8 to issue new guidance for healthcare providers to use the two arthritis drugs for severely ill patients, reports the Times.
While some scientists not involved with the study have called the findings promising, others have taken a more cautious approach.
“I guess I would interpret with caution until this was published in a peer-reviewed journal,” said Lauren Henderson, MD, a rheumatologist at Boston Children’s Hospital, told the Times.
More articles on patient safety and outcomes:
10 top patient safety issues for 2021
COVID-19 ‘long haulers’ identify 205 virus symptoms
DC hospitals treat victims of Capitol riot: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.